BidaskClub Downgrades Global Blood Therapeutics (GBT) to Buy

Global Blood Therapeutics (NASDAQ:GBT) was downgraded by BidaskClub from a “strong-buy” rating to a “buy” rating in a note issued to investors on Wednesday, December 20th.

Several other equities research analysts also recently weighed in on GBT. Needham & Company LLC set a $51.00 price target on Global Blood Therapeutics and gave the stock a “buy” rating in a report on Tuesday, October 24th. Oppenheimer set a $53.00 price target on Global Blood Therapeutics and gave the stock a “buy” rating in a report on Wednesday, October 11th. Zacks Investment Research downgraded Global Blood Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, October 16th. HC Wainwright set a $73.00 price target on Global Blood Therapeutics and gave the stock a “buy” rating in a report on Monday, December 11th. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $56.00 price target (up from $51.00) on shares of Global Blood Therapeutics in a report on Friday, October 6th. One research analyst has rated the stock with a sell rating, one has given a hold rating and fourteen have issued a buy rating to the stock. Global Blood Therapeutics has an average rating of “Buy” and a consensus target price of $62.07.

Shares of Global Blood Therapeutics (GBT) traded up $0.15 during mid-day trading on Wednesday, reaching $56.60. The company’s stock had a trading volume of 968,500 shares, compared to its average volume of 1,824,567. Global Blood Therapeutics has a fifty-two week low of $14.70 and a fifty-two week high of $57.75. The stock has a market capitalization of $2,600.00 and a P/E ratio of -22.20.

Global Blood Therapeutics (NASDAQ:GBT) last issued its quarterly earnings results on Thursday, November 2nd. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.04). During the same period in the previous year, the firm posted ($0.58) earnings per share. research analysts expect that Global Blood Therapeutics will post -2.54 earnings per share for the current year.

In other Global Blood Therapeutics news, VP Peter Radovich sold 12,500 shares of the stock in a transaction on Monday, October 30th. The stock was sold at an average price of $35.00, for a total transaction of $437,500.00. Following the sale, the vice president now owns 2,684 shares of the company’s stock, valued at approximately $93,940. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Jung Choi sold 3,000 shares of the stock in a transaction on Tuesday, October 17th. The shares were sold at an average price of $32.65, for a total value of $97,950.00. Following the sale, the insider now directly owns 138,455 shares in the company, valued at approximately $4,520,555.75. The disclosure for this sale can be found here. Insiders have sold a total of 103,500 shares of company stock worth $3,773,000 over the last 90 days. 5.30% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in GBT. BNP Paribas Arbitrage SA boosted its position in Global Blood Therapeutics by 694.9% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,547 shares of the company’s stock valued at $124,000 after acquiring an additional 3,975 shares in the last quarter. Jane Street Group LLC bought a new stake in Global Blood Therapeutics during the 3rd quarter valued at $200,000. Trexquant Investment LP bought a new stake in Global Blood Therapeutics during the 3rd quarter valued at $202,000. Dynamic Technology Lab Private Ltd bought a new stake in Global Blood Therapeutics during the 3rd quarter valued at $205,000. Finally, DekaBank Deutsche Girozentrale bought a new stake in Global Blood Therapeutics during the 2nd quarter valued at $211,000. 85.72% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “BidaskClub Downgrades Global Blood Therapeutics (GBT) to Buy” was published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this story on another site, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://ledgergazette.com/2018/01/13/global-blood-therapeutics-gbt-downgraded-to-buy-at-bidaskclub.html.

About Global Blood Therapeutics

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).

Analyst Recommendations for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply